NasdaqGS:SRPTBiotechs
A Look At Sarepta Therapeutics (SRPT) Valuation After Fresh FDA Feedback And ELEVIDYS Safety Study Update
Regulatory and Clinical Updates Put Sarepta Therapeutics (SRPT) in Focus
Sarepta Therapeutics (SRPT) has drawn fresh investor attention after receiving FDA feedback that supports supplemental applications for AMONDYS 45 and VYONDYS 53, alongside new enrollment activity in its ELEVIDYS ENDEAVOR Cohort 8 safety study.
See our latest analysis for Sarepta Therapeutics.
Despite the fresh FDA and clinical updates, Sarepta's recent share price performance has been weak, with a 1 month share price...